(2S,3R)-6,8-dichloro-2-(trifluoromethyl)-3,4-dihydro-2H-chromene-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (2S,3R)-6,8-dichloro-2-(trifluoromethyl)-3,4-dihydro-2H-chromene-3-carboxylic acid
• 化学式: C₁₁H₇Cl₂F₃O₃
• 分子量: 315.07
• InChiKey: HABGWKJODZJASK-MUWHJKNJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders
  申请人：——

  公开号：US20030232844A1

  公开（公告）日：2003-12-18

  A class of dihydrobenzopyrans, dihydrobenzothiopyrans, tetrahydroquinolines, tetraydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula (I) wherein X, A 1 , A 2 , A 3 , A 4 , R, R″, R 1 and R 2 are as described in the specification. 1

  本文介绍了一类二氢苯并吡喃、二氢苯并硫喹啉、四氢喹啉、四氢萘和类似物，用于治疗环氧合酶-2介导的疾病。特别感兴趣的化合物由公式（I）定义，其中X，A1，A2，A3，A4，R，R″，R1和R2如规范中描述。
• Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders
  申请人：Rogier Donald

  公开号：US20050010050A1

  公开（公告）日：2005-01-13

  A class of dihydrobenzopyrans, dihydrobenzothiopyrans, tetrahydroquinolines, tetrahydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula (I) wherein X, A 1 , A 2 , A 3 , A 4 , R, R″, R 1 and R 2 are as described in the specification.

  描述了一类二氢苯并吡喃、二氢苯并噻吩、四氢喹啉、四氢萘及其类似物，用于治疗环氧合酶-2介导的疾病。特别感兴趣的化合物由公式（I）定义，其中X、A1、A2、A3、A4、R、R″、R1和R2如规范所述。
• DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS
  申请人：Pharmacia Corporation

  公开号：EP1274700B1

  公开（公告）日：2004-11-17
• COX-2 Inhibitors for the Treatment of Ocular Disease
  申请人：Vrbanac, JR. John James

  公开号：US20200237715A1

  公开（公告）日：2020-07-30

  There is provided a pharmaceutical composition suitable for topical administration to an eye, which contains a selective COX-2 inhibitory drug or salt thereof having a high water solubility and lipophilicity, concomitant with high potency, in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and one or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the composition has an effective residence time of about 1 to about 36 hours. Also provided is a method and kit for treating and/or preventing a disease or disorder in an eye, the method comprises administering to the eye a composition of the present disclosure.
• US6822102B2
  申请人：——

  公开号：US6822102B2

  公开（公告）日：2004-11-23